The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(2010) In Blood 115(8). p.1530-1533- Abstract
- Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk... (More)
- Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1568349
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 115
- issue
- 8
- pages
- 1530 - 1533
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000274974200010
- scopus:77949890943
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2009-08-236570
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)
- id
- ae56377f-6cae-4c0f-966d-5e94b2bd8cb1 (old id 1568349)
- date added to LUP
- 2016-04-01 10:41:34
- date last changed
- 2022-04-28 00:27:49
@article{ae56377f-6cae-4c0f-966d-5e94b2bd8cb1, abstract = {{Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.}}, author = {{Geisler, Christian H. and Kolstad, Arne and Laurell, Anna and Raty, Riikka and Jerkeman, Mats and Eriksson, Mikael and Nordstrom, Marie and Kimby, Eva and Boesen, Anne Marie and Nilsson-Ehle, Herman and Kuittinen, Outi and Lauritzsen, Grete F. and Ralfkiaer, Elisabeth and Ehinger, Mats and Sundstrom, Christer and Delabie, Jan and Karjalainen-Lindsberg, Marja-Liisa and Brown, Peter and Elonen, Erkki}}, issn = {{1528-0020}}, language = {{eng}}, number = {{8}}, pages = {{1530--1533}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)}}, url = {{http://dx.doi.org/10.1182/blood-2009-08-236570}}, doi = {{10.1182/blood-2009-08-236570}}, volume = {{115}}, year = {{2010}}, }